Journal article
IV steroids during long episodes of Kleine-Levin syndrome.
- Léotard A From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Groos E From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Chaumereuil C From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Peter-Derex L From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Rossetti AO From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Leu-Semenescu S From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland.
- Arnulf I From the Sleep Disorders Unit (A.L., E.G., C.C., S.L.-S., I.A.), National Reference Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Brain Research Institute (CRICM, UPMC, Paris 6; Inserm UMR_S 975; CNRS UMR 7225), Sorbonne University Paris; Sleep Medicine and Respiratory Disease Center (L.P.-D.), Competence Center for Narcolepsy, Hypersomnia and Kleine-Levin Syndrome, Hospices Civils de Lyon, France; and Center for Investigation and Research in Sleep (A.O.R.), Lausanne University Hospital and Lausanne University, Switzerland. isabelle.arnulf@aphp.fr.
- 2018-03-25
Published in:
- Neurology. - 2018
Administration, Intravenous
Adolescent
Adult
Female
Humans
Kleine-Levin Syndrome
Male
Methylprednisolone
Neuroprotective Agents
Retrospective Studies
Treatment Outcome
Young Adult
English
OBJECTIVE
To retrospectively compare the benefits (episode cessation) and risks of IV methylprednisolone (IV-MP) vs abstention during prolonged Kleine-Levin syndrome (KLS) episodes.
METHODS
A total of 26 patients with KLS received 1 g/d IV-MP for 3 days during 1 to 6 episodes each (totaling 43 IV-MP sessions). The change of episode duration with IV-MP (vs previous episode duration) was compared with the change duration between 2 consecutive episodes in 48 untreated patients matched for age, sex, age at KLS onset, number of episodes, and disease duration (more treated than untreated patients had long episodes).
RESULTS
Eleven patients (42.3%) had an episode that was at least 1 week shorter than the preceding one when they received IV-MP therapy, whereas shorter episodes were significantly less frequent (10.4%) in the untreated group. This benefit was more marked (65.5% responders, 12 fewer days in an episode vs 0 days in the untreated patients) when IV-MP was infused before the 10th day of the episode. Mild, transient adverse effects (insomnia, muscle pain, nervousness/restlessness, but no manic switching) were reported by 61.3% of patients. No specific responder profile was identified.
CONCLUSION
In this open-labeled, naturalistic study, early IV-MP (following the protocol for multiple sclerosis relapses) had a good benefit/risk ratio during KLS episodes in patients with long episodes (with half of the patients having an early cessation of episodes).
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence that for patients with long episodes of KLS, IV steroids decrease the duration of KLS episodes.
To retrospectively compare the benefits (episode cessation) and risks of IV methylprednisolone (IV-MP) vs abstention during prolonged Kleine-Levin syndrome (KLS) episodes.
METHODS
A total of 26 patients with KLS received 1 g/d IV-MP for 3 days during 1 to 6 episodes each (totaling 43 IV-MP sessions). The change of episode duration with IV-MP (vs previous episode duration) was compared with the change duration between 2 consecutive episodes in 48 untreated patients matched for age, sex, age at KLS onset, number of episodes, and disease duration (more treated than untreated patients had long episodes).
RESULTS
Eleven patients (42.3%) had an episode that was at least 1 week shorter than the preceding one when they received IV-MP therapy, whereas shorter episodes were significantly less frequent (10.4%) in the untreated group. This benefit was more marked (65.5% responders, 12 fewer days in an episode vs 0 days in the untreated patients) when IV-MP was infused before the 10th day of the episode. Mild, transient adverse effects (insomnia, muscle pain, nervousness/restlessness, but no manic switching) were reported by 61.3% of patients. No specific responder profile was identified.
CONCLUSION
In this open-labeled, naturalistic study, early IV-MP (following the protocol for multiple sclerosis relapses) had a good benefit/risk ratio during KLS episodes in patients with long episodes (with half of the patients having an early cessation of episodes).
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence that for patients with long episodes of KLS, IV steroids decrease the duration of KLS episodes.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1212/WNL.0000000000005349
- PMID 29572278
- Persistent URL
- https://folia.unifr.ch/global/documents/257487
Statistics
Document views: 9
File downloads: